| Title: |
Exploiting NRF2‐ARE pathway activation in papillary renal cell carcinoma. |
| Authors: |
Angori, Silvia, Lakshminarayanan, Harini, Banaei‐Esfahani, Amir, Mühlbauer, Katharina, Bolck, Hella Anna, Kallioniemi, Olli, Pietiäinen, Vilja, Schraml, Peter, Moch, Holger |
| Source: |
International Journal of Cancer; Apr2025, Vol. 156 Issue 7, p1457-1469, 13p |
| Subject Terms: |
NUCLEAR factor E2 related factor, RENAL cell carcinoma, THERAPEUTICS, DRUG discovery, DOWNREGULATION, NAD(P)H dehydrogenases, CELLULAR signal transduction |
| Abstract: |
Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype but has no indicated targeted treatments. MET inhibition may be a treatment for MET‐driven pRCC, but there is a large group of non‐MET‐driven pRCC without targeted therapy. Activation of NRF2‐ARE pathway has been suggested to be involved in pRCC. To study the relevance of the NRF2‐ARE pathway, we characterized 60 pRCCs by copy number analysis and Whole Exome Sequencing. Because stabilisation of NRF2 results in enhanced expression of NQO1, a reductase that prevents production of reactive oxygen species, protein expression of NQO1 was analysed by immunohistochemistry (IHC) from tissue microarrays (TMAs) and by enzymatic activity assay. Finally, patient‐derived pRCC cells (PDCs) were applied for drug profiling with 18 NRF2‐ARE pathway inhibitors. We identified MET mutations in 5%, and mutations in four genes of NRF2‐ARE pathway (NFE2L2, KEAP1, CUL3 and BACH1) in 10% of 60 pRCC samples. IHC analysis of TMAs of 638 renal cancers showed the correlation of the expression of NQO1 with poor survival outcome (p <.001) and high tumour grade (p <.001) and stage (p <.001) in pRCC. NQO1 mRNA, protein levels and enzymatic activity were increased in 56% of matched pRCC tissue samples and patient‐derived cells (PDCs, n = 9). Drug screening revealed that Brusatol and Convallatoxin are potential novel drugs for pRCC. Inhibition of NRF2 represents a novel therapeutic approach for MET‐independent pRCC patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
